Takeda Pharmaceutical trades at an attractively valued forward price-to-earnings of 29.8x for a global pharma with 186% free cash flow conversion and 31% analyst upside, but three consecutive earnings misses and weak revenue growth signal the business has not yet demonstrated the execution quality needed to close the valuation gap.
Thesis pillars
- Exceptional Free Cash Flow Conversion→Stable
- Analyst Consensus Significant Upside↑Improving
- Consecutive Earnings Miss Record↑Improving
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026
Takeda Pharmaceutical Company L (TAK) Stock Analysis
Healthcare · Drug Manufacturers - Specialty & Generic
Wait for pullback to $19.84. Price sits above the model's entry target of $19.84; the risk/reward becomes favorable on a pullback. Key risks: Analyst target reached - limited upside remaining; Near 52-week high (1.9% away).
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and... Read more
Wait for pullback to $19.84. Price sits above the model's entry target of $19.84; the risk/reward becomes favorable on a pullback. Key risks: Analyst target reached - limited upside remaining; Near 52-week high (1.9% away). Chart setup: No clear chart pattern; technical signals are mixed. Earnings today. Wait until post-earnings. Score 5.2/10, moderate confidence.
Passes 6/9 gates (positive momentum, clean insider activity, no SEC red flags, news boost earnings 0.80, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 0d<=7d. Suitability: moderate.
Recent developments
updated 2026-10-29Recent Developments — Takeda Pharmaceutical Company L
Latest news
- NEWS TAK|Takeda Pharmaceutical Co Ltd|Price:17.095|Chg%:-0.655 - TradingKey — TradingKey neutral
- NEWS Takeda stock: Analysts lift target for Takeda stock to USD 20.74 - AD HOC NEWS — AD HOC NEWS positive
- NEWS TAK stock: results scheduled for October 29, 2026 pre-market - ad-hoc-news.de — ad-hoc-news.de neutral
- NEWS Takeda Pharmaceutical Company Limited 2026 Q4 - Results - Earnings Call Presentation (NYSE:TAK) 2026-05-13 - Seeking Alp — Seeking Alpha neutral
- NEWS What's Going On With Takeda Stock Wednesday? - Takeda Pharmaceutical Co (NYSE:TAK) - Benzinga — Benzinga neutral
Generated 2026-10-29T11:53:52Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $19.84. Price sits above the model's entry target of $19.84; the risk/reward becomes favorable on a pullback. Key risks: Analyst target reached - limited upside remaining; Near 52-week high (1.9% away). Chart setup: No clear chart pattern; technical signals are mixed. Earnings today. Wait until post-earnings. Analyst target $19.25 reached (−4.5%), stop $19.10 (−5.5%), A.R:R -0.4:1. Score 5.2/10, moderate confidence.
Analyst target $19.25 reached (−4.5% from $20.15); no take-profit level is published. Analyst target $19.25 reached (−4.5%), stop $19.10 (−5.5%), A.R:R -0.4:1. Stop-loss: $19.10.
Analyst target reached - limited upside remaining; Near 52-week high (1.9% away); V7 low-quality RISK_OFF penalty: -0.5 (Q=4.6).
Takeda Pharmaceutical Company L trades at a P/E of N/A (forward 38.0). TrendMatrix value score: 7.2/10. Verdict: Buy (Wait for Entry).
21 analysts cover TAK with a consensus score of 3.9/5. Average price target: $23.
What does Takeda Pharmaceutical Company L do?Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing...
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.